Sugi Predict

Sugi Predict / Compounds / SCHEMBL7601178

SCHEMBL7601178

SCHEMBL7601178

CC(=O)c1cnc2cc(Br)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HPGDS O60760 10/20 0.47
▸ MGAM O43451 1/20 0.44
▸ HTT P42858 3/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ MAP4K4 O95819 1/20 0.42
▸ CSNK1G2 P78368 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ MAP4K5 Q9Y4K4 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ KDR P35968 1/20 0.39
▸ CYP2A6 P11509 1/20 0.39
▸ IRAK4 Q9NWZ3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9637 0.87 HTT (0.46) HPGDSMGAMHTTCYP1A2CYP2C19
SCHEMBL1352602 0.85 MGAM (0.62) HPGDSMGAMHTTCYP1A2CYP2C19
SCHEMBL4541927 0.83 HPGDS (0.61) HPGDSMGAMHTTCYP1A2CYP2C19
SCHEMBL2001821 0.83 HPGDS (0.51) HPGDSHTTTSHR
SCHEMBL14215687 0.81 HPGDS (0.45) HPGDSMGAMHTTCYP1A2CYP2C19
SCHEMBL7600509 0.81 GSK3B (0.49) HPGDSMGAMHTTCYP1A2CYP2C19
SCHEMBL26242992 0.80 HPGDS (0.50) HPGDSMGAMHTTMAP4K4CSNK1G2
SCHEMBL4538765 0.79 MAOB (0.61) HPGDSHTTCYP2C19ALDH1A1
SCHEMBL7600387 0.78 HPGDS (0.46) HPGDS
SCHEMBL26240998 0.78 EGFR (0.51) HPGDSMGAMMAP4K4CSNK1G2CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952380-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors LUPIN LIMITED (IN) 2024-04-09 — — US disclosed
CN-111712498-B Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors 鲁平有限公司 2023-09-29 — — CN disclosed
US-11459330-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors LUPIN LIMITED (IN) 2022-10-04 — — US disclosed
US-20220267339-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS LUPIN LIMITED (IN) 2022-08-25 — — US disclosed
EP-3724190-B1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS LUPIN LTD (IN) 2022-07-06 — — EP disclosed
US-20210163486-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS LUPIN LIMITED (IN) 2021-06-03 — — US disclosed
CN-111712498-A Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors 鲁平有限公司 2020-09-25 — — CN disclosed
US-20150057218-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS INC (US) 2015-02-26 — — US disclosed
US-20150057218-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS INC (US) 2015-02-26 — — US disclosed
US-8921369-B2 Inhibitors of HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2014-12-30 — — US disclosed
EP-2373172-B1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS INC (US) 2013-07-17 — — EP disclosed
US-20130096101-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2013-04-18 — — US disclosed
US-20130096101-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2013-04-18 — — US disclosed
WO-2012123298-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-20 — — WO disclosed
US-20120230951-A1 ANTIVIRAL COMPOUNDS ALAM MUZAFFAR (US) 2012-09-13 — — US disclosed
WO-2010065674-A9 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2012-05-31 — — WO disclosed
US-20120122864-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2012-05-17 — — US disclosed
US-20120122864-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2012-05-17 — — US disclosed
WO-2011149856-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2011-12-01 — — WO disclosed
WO-2010065674-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2010-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11459330-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 HPGDS 3366/4885MGAM 2651/4885HTT 1810/4885
US-20130096101-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 HPGDS 2418/4885MGAM 4043/4885HTT 3674/4885
US-20210163486-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 HPGDS 3366/4885MGAM 2651/4885HTT 1810/4885
US-20120122864-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 HPGDS 2085/4885MGAM 4158/4885HTT 3798/4885
US-20150057218-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 HPGDS 2085/4885MGAM 4158/4885HTT 3798/4885
US-20220267339-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 HPGDS 3366/4885MGAM 2651/4885HTT 1810/4885
US-11952380-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 HPGDS 3366/4885MGAM 2651/4885HTT 1810/4885
US-20120230951-A1 ANTIVIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS HPGDS 1113/4885MGAM 4055/4885HTT 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.